vimarsana.com

Latest Breaking News On - Respiratory tract diseases - Page 1 : vimarsana.com

Pfizer Stock Has 29% Upside, Says a New Bull

Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.

Emily dattiloCourtesy pfizerVamil divanDow jones marketWall streetArticle normalRetail wholesaleHealthcare life sciencesClothing textilesConsumer goodsSpecialized drugs medicationsFinancial performanceEarnings surprisesAnalysts amp 39 comments recommendationsCorporate industrial newsPolitical general news

Moderna posts surprise quarterly profit even as COVID sales continue to slide

Moderna on Thursday reported a surprise fourth-quarter profit even as its COVID product sales continue to plunge.

Moderna spikevaxStephane bancelCenters for diseaseDrug administrationMerck coVaccine allianceModerna incChief financial officer jamey mockExecutive stephane bancelDisease controlArticle normalRetail wholesaleHealthcare life sciencesClothing textilesConsumer goodsSpecialized drugs medications

Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations

Vaccine maker Moderna reported a profit of 55 cents a share on revenue of $2.8 billion in the December quarter, beating analysts’ expectations.

Jack dentonGetty imagesWall streetArticle normalBiotechnology servicesHealthcare life sciencesSpecialized drugs medicationsFinancial performanceSales figuresEarnings projectionsCorporate industrial newsPolitical general newsRespiratory tract diseasesMedical conditionsNovel coronavirusesInfectious diseases

Novavax Stock Soars 26% A Vaccine Purchase Settlement Is One Reason Why

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

John jacobsAngela palumboDrug administrationGetty imagesNovavax chief executiveDow jones marketWall streetArticle normalHealthcare life sciencesClothing textilesConsumer goodsSpecialized drugs medicationsFinancial performanceCorporate industrial newsPolitical general newsRespiratory tract diseases

RAPT Therapeutics stock plunges as FDA halts two clinical trials

RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its.

Brian wongRapt therapeutics incDrug administrationGoldman sachsArticle normalBiotechnology servicesComputers consumer electronicsApplications softwareHealthcare life sciencesRegulation government policyNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general news

vimarsana © 2020. All Rights Reserved.